
A
G0/G1
S+G2/M
BT474
Control
Trastuzumab
60.3%
39.7%
69.8%
30.2%
Counts (x10³)
PI
BTRH
63.9%
36.1%
63.7%
36.3%
BTSH
68.4%
31.6%
76.5%
24.5%
B
BT474
Control
Trastuzumab 96h
2.2%
1.3%
7.8%
2.7%
ANN
Non-viable
Viable
Cell percentage (%)
10.6
89.4
13.2
86.8
C
T
C
SKBR3
6.5%
3.2%
8%
6.4%
15.4
84.6
18.8
81.3

Figure S2